0000899243-22-013881.txt : 20220405
0000899243-22-013881.hdr.sgml : 20220405
20220405190017
ACCESSION NUMBER: 0000899243-22-013881
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220401
FILED AS OF DATE: 20220405
DATE AS OF CHANGE: 20220405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gould Robert J
CENTRAL INDEX KEY: 0001577034
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38978
FILM NUMBER: 22808826
MAIL ADDRESS:
STREET 1: C/O EPIZYME, INC.
STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc.
CENTRAL INDEX KEY: 0001680581
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474839948
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-651-8851
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-04-01
0
0001680581
Fulcrum Therapeutics, Inc.
FULC
0001577034
Gould Robert J
C/O FULCRUM THERAPEUTICS, INC.
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2022-04-01
4
M
0
34464
7.84
A
541094
D
Common Stock
2022-04-01
4
S
0
34464
24.0297
D
506630
D
Common Stock
2022-04-04
4
M
0
7235
7.84
A
513865
D
Common Stock
2022-04-04
4
S
0
7235
24.0151
D
506630
D
Common Stock
2022-04-05
4
M
0
52552
7.84
A
559182
D
Common Stock
2022-04-05
4
S
0
52552
24.2574
D
506630
D
Stock Option (right to buy)
7.84
2022-04-01
4
M
0
34464
0.00
D
2029-01-21
Common Stock
34464
289998
D
Stock Option (right to buy)
7.84
2022-04-04
4
M
0
7235
0.00
D
2029-01-21
Common Stock
7235
282763
D
Stock Option (right to buy)
7.84
2022-04-05
4
M
0
52552
0.00
D
2029-01-21
Common Stock
52552
230211
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.17, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.75, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.
/s/ Curt Oltmans, as attorney-in-fact for Robert J. Gould
2022-04-05